IDEXX Reports Strong Q2 Results, Raises Full-Year Revenue and EPS Guidance
IDXX sits 15% above its 52-week low of $518.55 on elevated volume (1.8× avg).
Summary
IDEXX Laboratories announced strong second-quarter 2026 financial results, with double-digit revenue and EPS growth, and subsequently raised its full-year revenue and EPS guidance.
Updates
· SEC 10-Q — 10-Q confirms Q2 revenue of $1,216.6 million, net income of $338.4 million, and diluted EPS of $4.27. Cash and equivalents were $196.9 million at June 30, 2026.
Key Events · Earnings and Guidance · IDXX
-
Strong Second Quarter Performance
Achieved $1,217 million in revenue, up 10% reported and 9% organic, with diluted EPS of $4.27, an increase of 18% reported and 15% on a comparable basis. Operating margin expanded by 140 basis points.
-
Raised Full-Year Revenue Guidance
Narrows 2026 revenue guidance to $4,700 million - $4,745 million, an increase of $5 million at the midpoint, reflecting strong CAG Diagnostics performance despite a $15 million foreign exchange headwind.
-
Increased Full-Year EPS Outlook
Raised 2026 EPS outlook to $14.69 - $14.94, an increase of $0.14 compared to prior guidance midpoint, driven by operational performance.
-
Continued Operational Strength
CAG Diagnostics recurring revenue grew 11% reported and 10% organic, with the IDEXX inVue Dx installed base surpassing 9,000 instruments.
Analysis · IDXX · Life Sciences
IDEXX Laboratories delivered robust second-quarter results, exceeding expectations with double-digit revenue and EPS growth. The company also raised its full-year 2026 revenue and EPS guidance, signaling continued operational strength and confidence in its outlook despite foreign exchange headwinds. This positive revision to guidance is a significant indicator for investors.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDXX was trading at $597.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.8B. The 52-week trading range was $518.55 to $769.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.